All preclinical studies that have examined the effect of adding an anti-TGF-β moiety to the CAR-T construct have shown greater T-cell recruitment, cytokine release and cytotoxicity in vitro, as well as greater tumour-growth suppression in vivo [100,101,102]. The gene discussed is TGFB1; the disease is neoplasm.